1. Home
  2. NTLA vs NWN Comparison

NTLA vs NWN Comparison

Compare NTLA & NWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • NWN
  • Stock Information
  • Founded
  • NTLA 2014
  • NWN 1859
  • Country
  • NTLA United States
  • NWN United States
  • Employees
  • NTLA N/A
  • NWN N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • NWN Oil/Gas Transmission
  • Sector
  • NTLA Health Care
  • NWN Utilities
  • Exchange
  • NTLA Nasdaq
  • NWN Nasdaq
  • Market Cap
  • NTLA 1.4B
  • NWN 1.5B
  • IPO Year
  • NTLA 2016
  • NWN N/A
  • Fundamental
  • Price
  • NTLA $13.80
  • NWN $43.19
  • Analyst Decision
  • NTLA Buy
  • NWN Strong Buy
  • Analyst Count
  • NTLA 17
  • NWN 2
  • Target Price
  • NTLA $56.63
  • NWN $43.50
  • AVG Volume (30 Days)
  • NTLA 3.1M
  • NWN 219.1K
  • Earning Date
  • NTLA 11-07-2024
  • NWN 11-12-2024
  • Dividend Yield
  • NTLA N/A
  • NWN 4.53%
  • EPS Growth
  • NTLA N/A
  • NWN N/A
  • EPS
  • NTLA N/A
  • NWN 2.06
  • Revenue
  • NTLA $43,086,000.00
  • NWN $1,137,832,000.00
  • Revenue This Year
  • NTLA $50.73
  • NWN N/A
  • Revenue Next Year
  • NTLA $8.69
  • NWN $3.62
  • P/E Ratio
  • NTLA N/A
  • NWN $21.00
  • Revenue Growth
  • NTLA N/A
  • NWN N/A
  • 52 Week Low
  • NTLA $12.82
  • NWN $34.82
  • 52 Week High
  • NTLA $34.87
  • NWN $43.30
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 36.15
  • NWN 68.53
  • Support Level
  • NTLA $12.82
  • NWN $40.38
  • Resistance Level
  • NTLA $17.30
  • NWN $41.87
  • Average True Range (ATR)
  • NTLA 1.11
  • NWN 0.96
  • MACD
  • NTLA -0.11
  • NWN 0.25
  • Stochastic Oscillator
  • NTLA 19.56
  • NWN 97.91

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About NWN Northwest Natural Holding Company

Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company generates its revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.

Share on Social Networks: